|
HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.
As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence in Hong Kong's long-term potential as a center for medical innovation.
Hong Kong has a supportive government ecosystem for healthcare innovation — its strategic initiatives to advance primary care and collaborative regional frameworks provide an ideal environment for Roche to deliver tailored solutions. Whether it is AI‑enabled diagnostics or advanced therapies, Roche is committed and eager to work alongside local partners to improve patient outcomes.
Looking ahead, Roche will continue strengthening its commitment to Hong Kong's scientific landscape and supporting the Primary Healthcare Blueprint through the following initiatives:
- Strengthening Diabetes and Chronic Disease Management – Advancing Point-of-Care Testing (POCT) to promote early intervention and better management of chronic diseases and introducing the first Continuous Glucose Monitoring (CGM) technology enhanced with AI algorithms for improved diabetes management.
- Driving Innovation in Ophthalmology – Developing innovative treatments that reduce the frequency of injections for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and broadening AI Optical Coherence Tomography (AI-OCT) screenings for the public.
- Pandemic Influenza Preparedness – Working with the government to enhance preparedness and strengthen economic resilience.
- Cancer and Precision Diagnostics – Expanding localized Comprehensive Genomic Profiling (CGP) to accelerate cancer diagnosis and treatment and AI-enabled digital pathology technology to enhance smart hospital facilities.
- Pioneering First-in-Human Clinical Research and Global Antiviral Drug Trials – Collaborating with multiple stakeholders, including academia, Roche initiated its First-in-Human (FIH) clinical trials in 2025, enrolling the world's first two Chinese patients. With groundbreaking global antiviral drug trials published in leading medical journals, Roche reaffirms its commitment to strengthening Hong Kong's position as a global hub for clinical research and innovation.
Ms. Amy Ho, General Manager of Roche Hong Kong Limited, said, "Hong Kong's vibrant healthcare ecosystem and strong policy support make it an ideal hub for innovation. At Roche, we are guided by our purpose statement, 'Doing now what patients need next'—through our collaboration with OASES, we are deepening our commitment to bring breakthrough therapies and diagnostics to patients faster, while nurturing local talent and research capabilities. This collaboration is not just about investment, it's about creating long-term value for patients, healthcare professionals, and society."
Mr. Ronald Lo, General Manager, Roche Diagnostics (Hong Kong) Limited, added: "According to the World Health Organisation, 75% of deaths are caused by chronic diseases[1], prompting a global shift from treatment to prevention as a long-term investment. Roche supports the Hong Kong Government's Primary Healthcare policy by advancing cutting‑edge diagnostics in chronic disease management. Through OASES, we aim to bring advanced diagnostic solutions to more patients, foster meaningful collaborations to build a sustainable healthcare system that improves lives."
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
For more information, please contact:
Butterfly Cheung
butterfly.cheung@roche.com
Iris Lam
iris.lam.il1@roche.com
Sincere Kwan
sincere.kwan@roche.com
References
1. World Health Organisation. Noncommunicable diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (Accessed Oct 10 2025)
HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.
As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence in Hong Kong's long-term potential as a center for medical innovation.
Hong Kong has a supportive government ecosystem for healthcare innovation — its strategic initiatives to advance primary care and collaborative regional frameworks provide an ideal environment for Roche to deliver tailored solutions. Whether it is AI‑enabled diagnostics or advanced therapies, Roche is committed and eager to work alongside local partners to improve patient outcomes.
Looking ahead, Roche will continue strengthening its commitment to Hong Kong's scientific landscape and supporting the Primary Healthcare Blueprint through the following initiatives:
- Strengthening Diabetes and Chronic Disease Management – Advancing Point-of-Care Testing (POCT) to promote early intervention and better management of chronic diseases and introducing the first Continuous Glucose Monitoring (CGM) technology enhanced with AI algorithms for improved diabetes management.
- Driving Innovation in Ophthalmology – Developing innovative treatments that reduce the frequency of injections for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and broadening AI Optical Coherence Tomography (AI-OCT) screenings for the public.
- Pandemic Influenza Preparedness – Working with the government to enhance preparedness and strengthen economic resilience.
- Cancer and Precision Diagnostics – Expanding localized Comprehensive Genomic Profiling (CGP) to accelerate cancer diagnosis and treatment and AI-enabled digital pathology technology to enhance smart hospital facilities.
- Pioneering First-in-Human Clinical Research and Global Antiviral Drug Trials – Collaborating with multiple stakeholders, including academia, Roche initiated its First-in-Human (FIH) clinical trials in 2025, enrolling the world's first two Chinese patients. With groundbreaking global antiviral drug trials published in leading medical journals, Roche reaffirms its commitment to strengthening Hong Kong's position as a global hub for clinical research and innovation.
Ms. Amy Ho, General Manager of Roche Hong Kong Limited, said, "Hong Kong's vibrant healthcare ecosystem and strong policy support make it an ideal hub for innovation. At Roche, we are guided by our purpose statement, 'Doing now what patients need next'—through our collaboration with OASES, we are deepening our commitment to bring breakthrough therapies and diagnostics to patients faster, while nurturing local talent and research capabilities. This collaboration is not just about investment, it's about creating long-term value for patients, healthcare professionals, and society."
Mr. Ronald Lo, General Manager, Roche Diagnostics (Hong Kong) Limited, added: "According to the World Health Organisation, 75% of deaths are caused by chronic diseases[1], prompting a global shift from treatment to prevention as a long-term investment. Roche supports the Hong Kong Government's Primary Healthcare policy by advancing cutting‑edge diagnostics in chronic disease management. Through OASES, we aim to bring advanced diagnostic solutions to more patients, foster meaningful collaborations to build a sustainable healthcare system that improves lives."
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
For more information, please contact:
Butterfly Cheung
butterfly.cheung@roche.com
Iris Lam
iris.lam.il1@roche.com
Sincere Kwan
sincere.kwan@roche.com
References
1. World Health Organisation. Noncommunicable diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (Accessed Oct 10 2025)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- The Shaw Prize Foundation announced its first major expansion in over two decades: the establishment of The Shaw Prize in Computer Science, a new prize category to honour pioneering breakthroughs in this transformative field that is reshaping the modern world.
 
The Shaw Prize Foundation announced on 28 January the establishment of a new prize category in Computer Science: https://youtu.be/8NWUlZxKsjg
Founded in 2002 by Hong Kong media mogul the late Mr Run Run Shaw, and first awarded in 2004, The Shaw Prize has honoured over 110 exceptional individuals in Astronomy, Life Science and Medicine, and Mathematical Sciences. With Computer Science now rapidly transforming every domain of our lives and scientific inquiry, the Foundation introduces this fourth prize to celebrate the field's foundational advances and their far-reaching impact on humanity.
The announcement came during a press conference on Wednesday, 28 January 2026, at the Hong Kong Convention and Exhibition Centre, drawing over 100 guests from academia, media, and other sectors.
Dr Raymond Chan, Chair of The Shaw Prize Foundation, opened by highlighting technology's dramatic reshaping of life and The Prize's enduring commitment to recognising excellence. "Computer Science is bursting with bold questions that push human thinking to new limits," he said, calling the addition a natural extension of Mr Shaw's vision.
Professor Kenneth Young, Chair of The Shaw Prize Council and Vice Chair of The Board of Adjudicators, emphasised that the new prize will operate in parallel with the three existing categories, following the same governance, selection guidelines, and monetary award of USD 1.2 million.
Professor Tony Chan, who chaired The Planning Committee for The Shaw Prize in Computer Science, expressed deep honour in leading the initiative, which involved convening top global experts to define the new prize's broad scope and guiding principles. He now serves as a Member of The Selection Committee.
Inaugural Chair of The Selection Committee, Professor Jennifer Chayes, Dean of the College of Computing, Data Science, and Society at the University of California, Berkeley, underscored Computer Science as a profound intellectual discipline, much like other basic sciences honoured by the Prize. This core scientific nature aligns seamlessly with the Prize's vision of honouring fundamental advances that benefit humankind. She urged invited field leaders to nominate candidates when nominations open from September to November 2026. The inaugural laureate(s) will be announced in spring 2027, alongside laureates of the other three prize categories.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The Shaw Prize Adds Computer Science in Landmark Expansion
